Dermatitis, Atopic
Pipeline by Development Stage
Drug Modality Breakdown
Dermatology is a $292M market that is mature and consolidating, dominated by a single blockbuster approaching loss of exclusivity.
Key Trends
- HUMIRA (adalimumab) dominates 88% of market spending but faces LOE in near-term, creating vulnerability
- Novel mechanisms like aryl hydrocarbon receptor agonists gaining traction with emerging products in peak lifecycle
- Substantial clinical trial activity (812 trials) suggests ongoing innovation pipeline despite mature market
Career Verdict
Dermatology offers stable near-term opportunities but requires strategic positioning given patent cliff risk and limited market size compared to other therapeutic areas.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | HUMIRA (adalimumab) | AbbVie | $258M | 88% | LOE_APPROACHING | Declining | |
| 2 | VTAMA (tapinarof) | Merck & Co. | $19M | 6% | PEAK | Growing | 13.4yr |
| 3 | ORACEA (doxycycline) | Galderma | $4M | 1% | LOE_APPROACHING | Declining | 1.5yr |
Drug Class Breakdown
Patent cliff looming
Emerging innovation
Mature segment
Niche applications
Career Outlook
StableDermatology represents a stable but narrow career path with limited growth compared to larger therapeutic areas; compensation is competitive in Commercial and Medical Affairs but R&D opportunities are scarce. HUMIRA's patent cliff creates near-term uncertainty for AbbVie but may drive restructuring and new product launches elsewhere. Market consolidation around a few large players (AbbVie, Regeneron, Merck) limits startup/biotech opportunities.
Breaking In
Enter via Commercial or Medical Affairs roles where hiring is highest; dermatology has lower scientific barrier to entry than oncology but requires strong relationship-building and market access acumen.
For Experienced Professionals
Leverage HUMIRA transition expertise or develop specialty in emerging mechanisms (retinoids, AhR agonists); consider moving to larger franchises (immunology, oncology) if seeking higher growth trajectory.
In-Demand Skills
Best For
Hiring Landscape
Dermatology shows concentrated hiring at AbbVie (52 positions) and Regeneron (46 positions), with Commercial roles dominating (89 jobs, $188K avg salary) and Medical Affairs roles commanding premium compensation ($386K avg). Limited R&D hiring (8 positions) suggests mature drug development phase with emphasis on commercialization and market access.
By Department
Commercial and Medical Affairs roles offer strong compensation and growth, but overall job market is small; best for professionals seeking revenue-generating functions rather than discovery roles.
Competitive Landscape
32 companies ranked by most advanced pipeline stage
+2 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 10,214 patients across 50 trials
A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application
Effect of Moisturising Creams on Skin Moisture in Atopic Dermatitis
Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis
Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis
Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis
A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis
Protopic Ointment in Adult Atopic Eczema of the Face
Protopic Ointment in Children Atopic Eczema
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis
A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
Study Of Atopic Dermatitis In Pediatrics
WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients
WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients
Long-term Safety of Protopic in Atopic Eczema
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.
A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032
A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated
Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis
Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
Evaluate the Safety, Tolerability of BAT6026
Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis
Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
A Study of LY3471851 in Participants With Eczema
Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation
A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis
A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream
Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients
Efalizumab for Moderate to Severe Atopic Dermatitis
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders
An Observational Study to Gather Real-World User Feedback on DIPROBASE® Advanced Eczema Cream in Adults and Children With Eczema or Dry Skin
Assessment of Clinical, Biological and Biometrological Paramaters in Adult Subjects Suffering From AD
A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area
Related Jobs in Dermatology
Head of Global Marketing & Launch Lead, Dermatology
Specialty Business Manager, Derm - Miami N, FL
Dermatology, Health & Science Specialist (SHSS) - Dayton, OH
Dermatology Territory Account Specialist – Lancaster / Allentown
Manager, Patient Access Brand Strategy & Operations – Dermatology
Associate Director, Patient Access Brand Strategy & Operations – Dermatology
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.